KAMADA LTD
No enriched coverage for $KMDA in the last 7 days.
No SEC Form 4 filings for $KMDA in the last 30 days.
See all $KMDA insider activity →Stifel reiterated a Buy rating and $11.00 price target on Kamada (KMDA), citing two new biosimilar launches. The stock has declined 8% in a week but the target implies 38% upside. Kamada plans to launch more biosimilars, aiming for $20M-$25M in sales by 2030. The company also secured a $50M plasma supply deal and presented positive CYTOGAM study results.
Kamada Ltd. launched two biosimilar products in Israel: Ustekinumab-Kamada and Enoxaparin-Kamada. The company expects its biosimilar portfolio to generate $4M in 2026, growing to $10M by 2028, and $20M-$25M by 2030. Kamada plans to add at least two more biosimilar products in 2027.
Kamada Ltd. (KMDA, KMDA.TA) confirmed sufficient inventory and capacity to meet increased U.S. demand for its KedRAB product, following a CDC advisory on rising rabies exposures. KedRAB is one of two FDA-approved anti-rabies treatments. The company cited its supply chain and partnerships as supportive factors. Kamada's stock is up 0.92% at ILA 2,517.
Recent KMDA coverage spans financial news, earnings and insider activity.
Analyst upgrade may support modest price appreciation.
The launch adds modest revenue potential and expands the biosimilar portfolio, likely supporting the stock modestly.
Kamada Ltd. (KMDA, KMDA.TA) confirmed sufficient inventory and capacity to meet increased U.S. demand for its KedRAB product, following a CDC advisory on rising rabies exposures. KedRAB is one of two FDA-approved anti-rabies treatments. The company cited its supply chain and partnerships as supportive factors. Kamada's stock is up 0.92% at ILA 2,517.
Insider sale may signal reduced confidence, potential short-term pressure on KMDA.
Significant insider sell may signal negative sentiment and pressure the stock lower.
AlphAI scores every news story that mentions KMDA with an AI model for sentiment and relevance, and aggregates insider trades from KAMADA LTD's SEC EDGAR Form 4 filings. Figures refresh continuously.
Stifel reiterated a Buy rating and $11.00 price target on Kamada (KMDA), citing two new biosimilar launches. The stock has declined 8% in a week but the target implies 38% upside. Kamada plans to launch more biosimilars, aiming for $20M-$25M in sales by 2030. The company also secured a $50M plasma supply deal and presented positive CYTOGAM study results.
1 min readKamada Ltd. launched two biosimilar products in Israel: Ustekinumab-Kamada and Enoxaparin-Kamada. The company expects its biosimilar portfolio to generate $4M in 2026, growing to $10M by 2028, and $20M-$25M by 2030. Kamada plans to add at least two more biosimilar products in 2027.
1 min readKamada Ltd. (KMDA, KMDA.TA) confirmed sufficient inventory and capacity to meet increased U.S. demand for its KedRAB product, following a CDC advisory on rising rabies exposures. KedRAB is one of two FDA-approved anti-rabies treatments. The company cited its supply chain and partnerships as supportive factors. Kamada's stock is up 0.92% at ILA 2,517.
2 min readTsur David sold 22,827 shares of KAMADA LTD (KMDA) at $8.18 ($0.19M total) on 2026-09-14.
1 min readTsur David sold 177,173 shares of KAMADA LTD (KMDA) at an average of $8.26 ($8.26–$8.28, $1.46M total) across 3 trades over 2026-09-07 to 2026-09-09.
1 min readKamada reported Q2 2026 earnings with record revenues of $54.9M (+23% YoY) and adjusted EBITDA of $14.1M (+29% YoY). The company reiterated its 2026 guidance of $200M-$205M in revenues and $50M-$53M in adjusted EBITDA. Growth is driven by existing products, with plans to accelerate through acquisitions and expanded distribution. Key products like KEDRAB and GLASSIA showed strong demand, and the company expects plasma sales to begin by year-end.
2 min readKamada Ltd. reported Q2 2026 results driven by double-digit growth in its commercial portfolio, led by KEDRAB. Management reiterated 2026 revenue guidance of $200 million to $205 million and a 26% adjusted EBITDA margin. It expects plasma sales to start in Q4, supported by a 3-year $50 million supply deal, plus biosimilar expansion and M&A. CFO Chaime Orlev will leave end-2026.
6 min readKamada Ltd. (NASDAQ: KMDA) reported record first-half 2026 results: revenues $100.2M (+13% YoY) and adjusted EBITDA $25.7M (+14% YoY), with net income $13.4M (+18%). Q2 revenues were $54.9M (+23%) and adjusted EBITDA $14.1M (+29%). It affirmed 2026 guidance: revenues $200M-$205M and adjusted EBITDA $50M-$53M, and signed a ~3-year ~$50M plasma supply agreement.
6 min readKAMADA LTD (KMDA) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance ● Record-High First Half Revenues of $100.2 Million, up 13% Year-over-Year
2 min readKamada (Nasdaq: KMDA; TASE: KMDA) said it signed a three-year normal source plasma supply agreement with a biopharmaceutical company. The deal is expected to generate about $50 million in revenue over three years, with initial commercial sales recorded in Q4 2026. Kamada noted its Texas collection centers are ramping to support the supply.
2 min read
